首页> 外文期刊>药物分析学报(英文) >S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)–Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview
【24h】

S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)–Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview

机译:S-亚硝基-N-乙酰基-L-半胱氨酸乙酯(SNACET)和N-乙酰基-L-半胱氨酸乙酯(NACET)–基于半胱氨​​酸的候选药物,具有独特的药理学特征,可作为NO,H2S和GSH的供应商进行口服作为抗氧化剂:结果和概述

获取原文
获取原文并翻译 | 示例
       

摘要

S-Nitrosothiols or thionitrites with the general formula RSNO are formally composed of the nitrosylcation(NO+)and a thiolate(RS-),the base of the corresponding acids RSH.The smallest S-nitrosothiol isHSNO and derives from hydrogen sulfide(HSH,H2S).The most common physiological S-nitrosothiols arederived from the amino acid L-cysteine(CysSH).Thus,the simplest S-nitrosothiol is S-nitroso-L-cysteine(CysSNO).CysSNO is a spontaneous potent donor of nitric oxide(NO)which activates soluble guanylylcyclase to form cyclic guanosine monophosphate(cGMP).This activation is associated with multiplebiological actions that include relaxation of smooth muscle cells and inhibition of platelet aggregation.Like NO,CysSNO is a short-lived species and occurs physiologically at concentrations around 1 nM inhuman blood.CysSNO can be formed from CysSH and higher oxides of NO including nitrous acid(HONO)and its anhydride(N2O3).The most characteristic feature of RSNO is the S-transnitrosation reaction bywhich the NO+group is reversibly transferred to another thiolate.By this way numerous RSNO can beformed such as the low-molecular-mass S-nitroso-N-acetyl-L-cysteine(SNAC)and S-nitroso-glutathione(GSNO),and the high-molecular-mass S-nitrosol-L-cysteine hemoglobin(HbCysSNO)present in erythrocytesand S-nitrosol-L-cysteine albumin(AlbCysSNO)present in plasma at concentrations of theorder of 200 nM.All above mentioned RSNO exert NO-related biological activity,but they must be administeredintravenously.This important drawback can be overcome by lipophilic charge-free RSNO.Thus,we prepared the ethyl ester of SNAC,the S-nitroso-N-acetyl-L-cysteine ethyl ester(SNACET),fromsynthetic N-acetyl-L-cysteine ethyl ester(NACET).Both NACET and SNACET have improved pharmacologicalfeatures over N-acetyl-L-cysteine(NAC)and S-nitroso-N-acetyl-L-cysteine(SNAC),respectively,including higher oral bioavailability.SNACET exerts NO-related activities which can be utilized in theurogenital tract and in the cardiovascular system.NACET,with high oral bioavailability,is a strong antioxidantand abundant precursor of GSH,unlike its free acid N-acetyl-L-cysteine(NAC).Here,we reviewthe chemical and pharmacological properties of SNACET and NACET as well as their analytical chemistry.We also report new results from the ingestion of S-[15N]nitroso-N-acetyl-L-cysteine ethyl ester(S15NACET)demonstrating the favorable pharmacological profile of SNACET.
机译:通式为RSNO的S-亚硝基硫醇或亚硫氰酸盐由亚硝酰基阳离子(NO +)和硫醇盐(RS-)组成,是相应酸RSH的碱。最小的S-亚硝基硫醇为HSNO,衍生自硫化氢(HSH,H2S) )。最常见的生理学S-亚硝基硫醇衍生自氨基酸L-半胱氨酸(CysSH)。因此,最简单的S-亚硝基硫醇是S-亚硝基-L-半胱氨酸(CysSNO).CysSNO是一氧化氮的自发强效供体( NO)激活可溶性鸟苷酸环化酶形成环鸟苷单磷酸(cGMP),这种激活与包括平滑肌细胞松弛和血小板聚集抑制在内的多种生物学作用有关.CysSNO是一种短命物种,在生理上以一定浓度存在大约1 nM的人类血液.CysSNO可以由CysSH和一氧化氮的高级氧化物(包括亚硝酸(HONO)及其酸酐(N2O3))形成.RSNO的最典型特征是S-亚硝基化反应NO +基团可逆地转移到另一种硫醇盐中。通过这种方式可以形成许多RSNO,例如低分子量S-亚硝基-N-乙酰基-L-半胱氨酸(SNAC)和S-亚硝基谷胱甘肽(GSNO),血浆中存在的高浓度S-亚硝基溶胶-L-半胱氨酸血红蛋白(HbCysSNO)和血浆中S-亚硝基溶胶-L-半胱氨酸白蛋白(AlbCysSNO)的浓度约为200 nM。相关的生物活性,但必须静脉给药。这一重要缺点可通过无亲脂性RSNO克服。因此,我们制备了SNAC的乙酯,S-亚硝基-N-乙酰基-L-半胱氨酸乙酯(SNACET) NACET和SNACET分别具有比N-乙酰-L-半胱氨酸(NAC)和S-亚硝基-N-乙酰-L-半胱氨酸(SNAC)更高的药理特性。 ,包括较高的口服生物利用度。SNACET发挥NO相关活性,可用于泌尿生殖道和心血管NACET具有很高的口服生物利用度,它是GSH的强抗氧化剂和丰富的前体,与它的游离酸N-乙酰基-L-半胱氨酸(NAC)不同。在这里,我们综述了SNACET和NACET的化学和药理性质以及它们的分析我们还报告了S- [15N]亚硝基-N-乙酰基-L-半胱氨酸乙酯(S15NACET)的摄入新结果,证明了SNACET的良好药理作用。

著录项

  • 来源
    《药物分析学报(英文)》 |2018年第001期|1-9|共9页
  • 作者单位

    Institute of Toxicology,Core Unit Proteomics,Hannover Medical School,30623 Hannover,Germany;

    Institute of Toxicology,Core Unit Proteomics,Hannover Medical School,30623 Hannover,Germany;

    Second Department of Cardiology,Jagiellonian University Medical College,Cracow,Poland;

    Department of Medicine,Surgery and Neuroscience,University of Siena,53100 Siena,Italy;

    Department of Life Sciences,Laboratory of Pharmacology and Toxicology,University of Siena,53100 Siena,Italy;

    Department of Analytical Chemistry,Faculty of Chemistry and Technology,University of Split,21000 Split,Croatia;

    Department of Urology and Urological Oncology,Hannover Medical School,30623 Hannover,Germany;

    Department of Urology and Urological Oncology,Hannover Medical School,30623 Hannover,Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:45:39
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号